Betamethasone has topical corticosteroid activity. The Presence of Neomycin should prevent the development of bacterial infection. Eye: For the short-term treatment of steroid responsive conditions of the eye when prophylactic antibiotic treatment is also required. after excluding the presence of fungal and viral disease. Ear: Otitis externa or other steroid responsive conditions where prophylactic antibiotic treatment is also required. Nose: Steroid responsive inflammatory conditions where prophylactic antibiotic treatment is also required.

Eye: 1 or 2 drops instilled into the eye (s) every one or two hours until control is achieved, when the frequency may be reduced. Ear: 2 or 3 drops instilled into the ear (s) every two or three hours until control is achieved, when the frequency can be reduced. Nose: 2 or 3 drops instilled into each nostril 2 or 3 times daily. CONTRA-INDICATIONS: Bacterial, Viral Fungal tuberculous or purulent condition of the eye. Use is contraindicated, if glaucoma is present or where herpetic keratitis is considered a possibility. Inadvertent use of topical steroids in the latter condition can lead to extension of the ulcer and marked visual deterioration. Hypersensitivity to the preparation. PRECAUTIONS: Steroids should not be administered to "red eyes" until a definite diagnosis has been made. Ophthalmological treatment with steroid preparations should not be repeated or prolonged without regular review to exclude raised intra-ocular pressure or unsuspected infections. USE IN PREGNANCY: There is inadequate evidence of safety in human pregnancy. Administration of Corticosteroids to pregnant animals can cause abnormalities of fetal development including cleff palate and intrauterine, growth retardation. There may therefore be a very small risk of such effects in the human fetus. SIDE-EFFECTS: Eye drops containing corticosteroids cause a serious rise in intra-ocular pressure in a small percentage of the population, including most of those with a family history of glaucoma, A milder rise may experience by a larger proportion of subjects if treatment is continued for longer than a few weeks. Thinning of the cornea leading to perforation has occurred with use of topical corticosteroids. Cataract is reported to have occurred after unduly prolonged treatment with topical corticosteroids. Excessive and prolonged intra-nasal usage above the recommended dose may induce systemic side effects.